John Chiminski: Thanks, Tom, and welcome, everyone to our earnings call. I’m joining today’s call from our Softgel facility in Aprilia, Italy where I just spent the day meeting with my local management team. Therefore, I will only be providing some opening comments and will then turn the call over to Matt. I’ll start by discussing our financial accomplishments for the fourth quarter, which was strong as we returned to year-over-year growth in revenue and adjusted EBITDA. As you can see on Slide 6, our revenue for the fourth quarter increased 4% as reported and increased 6% in constant currency to $532 million, all which was organic with all reporting segments contributing to the growth. On a full year basis, we continue to be pleased with our top-line performance and recorded year-on-year revenue growth of 6% on a constant currency basis, despite the challenges related to the Beinheim plant suspension from November through April and the softness we experienced in the fiscal year 2016 within our MRT product portfolio. Our adjusted EBITDA of $141.8 million was above the fourth quarter of fiscal year 2015 on a constant currency basis by 7% primarily due to our newly formed Drug Delivery Solutions segment. Matt will provide some additional detail related to our segment reporting changes later in the presentation. Our adjusted net income was $64.9 million or $0.52 per diluted share for the fourth quarter. Additionally, we saw a record year from a development, revenue and new product introduction perspective both of which we view as indicators of future commercial revenue growth. Now moving to our key operating accomplishments during the quarter. During the quarter, OPKO Health's NDA for RAYALDEE was approved by the FDA for treatment of patients with conditions related to chronic kidney disease and marks the first FDA approved product using Catalent’s proprietary official Softgel technology which is a non-gelatin plant based shell formulation and the first ever extended release prescription Softgel approved. We are pleased that OptiShell was selected as the optimum delivery method for the product and that we were able to help OPKO bring this important drug to approval. We also announced the launch of our clinical supply fast chain service during the fourth quarter which enables us to operate at greater speed and with greater flexibility and efficiency in the management and distribution of global clinical supply for our customers and their trial participants. We have seen significant interest from many of our CSS customers who are looking for more flexible and innovative solutions to get to the clinic faster and are already working with major pharmaceutical customers using this approach. Finally, in the fourth quarter we began moving forward with the $34 million expansion of our Madison Biologics facility which will add a 2/2,000 liter single use bioreactor system to our capacity to meet customer demand for this fast growing business. The new suite will be capable of running either 2,000 liter or 4,000 liter batches to support late-phase clinical and commercial production for our customers using single use bioreactor technology. This expansion is an important part of our growth strategy, and builds on previous investments in our biologics capabilities. In conclusion, I want to reiterate that dynamics of our industry and market remains very favorable and our customers' needs for fewer, bigger, better supplies will continue to be drivers of long-term growth. Now I'd like to turn the call over to our Executive Vice President & Chief Financial Officer, Matt Walsh.
John Chiminski: Sure John. So, we talked about the capital expenditure project to expand our capacity and biologics. We put just under $30 million into the Madison facility just a couple of years ago, that capacity is more or less already called for and the investments that we'll make will enable us to continue to accommodate the strong organic growth that we see within the biologics business. So that's good. I expect to see increasing asset utilization in the DDS segment specifically within the MRT business the Winchester expansion which we made over the last couple of years we will be able to grow into that over the next probably the next three to five years. So we should see good margin expansion opportunity because of that. And then I think the rest of the network is pretty balanced.
John Chiminski: So I will start with the first part Sean. So, for the first three quarters of the year you're quite correct that we saw volume declines in some of our higher margin products in the controlled release segment that started turnaround in the fourth quarter and more normal order patterns returned for those products during the quarter that gave us confidence when we were putting together the FY17 guidance that we would see order patterns in FY17 that more parallels FY16 and years prior and the patient consumption for those medications because part of -- a significant part of reasons why we were seeing lower volumes in the first three quarters of FY16 were supply chain issues and our customers had sufficient inventories of the products we were making. Those inventory stores have been worked down and we expect in FY17 that our manufactured volumes were closely parallel, patient consumption of the product and started to see and the confidence that we have that that will be the case is the actual volumes that we manufactured in Q4. And in terms of the growth rate year-on-year across the entire MRT portfolio was down about 5% to 7% year-on-year and we expect in '17 that will effect, that growth will rebound in the MRT business, it will look more like our long-term expectation of 4 to 6, what is good about that is that we are thinking these are relatively higher margin products in the controlled release segment, so the bottom-line impact should be good.
John Chiminski: That should be towards the higher end of our 4 to 6 expectation maybe even a little bit beyond the high-end.
John Chiminski: Thank you, operator. In conclusion, we're pleased with the favorable trends in our base business and a return to year-over-year growth in revenue and EBITDA in the fourth quarter. We look forward to carrying this momentum in the fiscal year 2017 as we turn the page on Beinheim and remain well positioned and capitalized in our industry leading partnerships. Thank you.
Matt Walsh: Sure, so let's start with our Softgel business which would be on the lower end of the 4% to 6% long-term outlook and the answers I am giving you Tejas are more of long-term oriented versus anything specific related to FY17 specifically so this is really the generally over the course of let's say a strategic planning time period, we would expect our Softgel business to grow towards the lower end of the 4 to 6. We would expect our new DDS segment to grow towards the middle to higher end of that 4% to 6% and our CSS business would also grow towards the higher end of that or even potentially a little above the higher end of the 4% to 6%.
Matt Walsh: So I think if you look at the midpoint of our guidance ranges, you would see that our adjusted EBITDA margin expectations for FY17 are a little bit above where they were full year FY16, so we do expect margin appreciation in FY17 versus ’16.
Matt Walsh: Sure, I will tell you that our level of interest and our level of effort expended on pursuing M&A activities have not changed. The deal flow that results from that is as you stated less than people's expectations, I would say it is probably less than management's expectation. But we continue to look for viable acquisition candidates that will improve our overall results and returns on capital and we will continue to do that in FY17. Just as a remainder, we completed three acquisitions in our first year out as a public company and then non-bearing FY16 but we have been just as active analyzing targets over that entire time period and that continues. So it's hard for me to predict when deals will cross the finish line and we're able to have announced complete a deal, but I can tell you in terms of capital deployment our overall strategy remains the same. We will continue to aggressively reinvest organically in the business that's our first priority to generate attractive returns on capital. Second priority would be growth through M&A to expand areas of our business where we can accelerate growth versus what we can do organically. You cited biologics as an example, I would say that that is certainly an area of the Company that we're aggressively growing organically John alluded to the $34 million capital expansion that we will be doing organically, we're also looking at external growth targets in that area as well.
Matt Walsh: Sure. I think the margin picture of this year and you gave part of the answer yourself Mark was Beinheim. The other piece of the equation for us is impacting margins in ’16 was the price, was the performance of the MRT product portfolio, where we experienced volume declines in some of our higher margin products. Obviously both of those situations are turning around in FY17 versus ’16. So we do see a recovery in margins coming and over a longer term horizon for the business that we would continue to see EBITDA margin expansion opportunities in the 200 to 300 basis point range as driven by principally asset utilization across our network, as well as our higher margin businesses growing preferentially faster than our lower margin businesses.
Matt Walsh: Sure. So in a long cycle business, we have -- which comprises our Softgel reporting segment, as well as the vast majority of our DDS reporting segment we go into every fiscal year with approximately 75% of that volume under contract. And while our firm order window is approximately 60 to 90 days, we are getting rolling annual forecast from our customers. So we have a good idea of what volumes are coming to us. So we start every fiscal year with good visibility into what the long cycle businesses will be doing. Where we see variability inevitably ends up being in new product launches and we try as best as we can to forecast the timing of those that is certainly challenging to do as product certainly launch later than our customers say that they will. But that’s where we tend to experience the most variability in terms of the otherwise quite stable outlook that we see for the focus of 7,000 products that we manufacture.
Matt Walsh: So, we are consolidating one of our sites data that was announced in November of 2015. We are consolidating our B side whale site into our other UK operating sites and that's occurring this year and a little bit into next year. And it comprises a large portion of the Q4 GAAP restructuring add backs in our adjusted EBITDA table.
Matt Walsh: No that was part of the explanation, it is not all the cost qualified for GAAP restructuring and if they don’t, we generally leave them in how we will report adjusted EBITDA. So, yes it was part of the margin explanation but it is, but some of our costs also show up in adjusted EBITDA calculations. The other parts of the margin bridge are related to the sales mix during the quarter. So we had relatively more comparative sales year-on-year and we also had more mix towards storage and distribution within the core part of the CSS offerings which, it comprised of manufacturing packaging and then storage and distribution of those two core activities we did relatively more storage and distribution revenue during the quarter which carries moderately lower margins than manufacturing and packaging.
Matt Walsh: No, I think it's, I think it's more just the Company's desire to put out a very responsible set of guidance figures that the Company will be, and has a very level of confidence in meeting.
Matt Walsh: That resides in the Softgel Technologies segment and the DDS segment there is no development revenue within the CSS segment.
Matt Walsh: So, it's less uncertainty as regards customers and products. What we're trying to be responsible about is the timing of when, not just production of certain products will resume but how the ramp will be and what sort of productivity, labor and equipment productivity progression we will see. So that's more of the driver of the range.
Matt Walsh: So that's a difficult question to answer at this point, what I can say is the estimates that we have put into our FY17 guidance are imminently achievable, we have a high level of confidence in the Beinheim projections that are part of that guidance.
Matt Walsh: Yes. So for net interest, we think we'll see something in the range of $90 million to $93 million this year FY17, and our effective tax rate will be in the range of 30% to 32%.
Matt Walsh: It's possible that the -- any changes in net interest expense are not as much driven by our actual bank debt as they are by the imputed interest expense related to capital leases Derik that's the only thing I am thinking of.
Matt Walsh: We didn't have any onetime milestone payments on the order that we have typically discussed which would be things like contract amendments or contract termination fees that would be sporadic in nature and would be the kind of thing you'd want to take into account as regards modeling. The milestone payments that I referred to in the prepared comments are absolutely normal course and we're looking to grow those just as part of our normal operations and where we I think I referenced that in the prepared comments was within in relation to our biologics business which that's how they're recognizing in revenue in the SMARTag business and the portion of our biologics manufacturing business, so that will absolutely continue.
Matt Walsh: We're not -- so I guess I would start by saying that we're not seeing any margin pressure within individual verticals. We may see mix moving quarter-to-quarter. I think in our Softgel business, our overall consumer health presence is growing that can come at lower margins, if or excluding the impact of Beinheim on the numbers this year what you would have seen was the margin impact of more consumer health business being offset by asset utilization that ended up being what we saw for ’16. For ’17, we are seeing that sort of stabilize ’17 versus ’16 within the Softgel business with the Beinheim recovery going to be overall margin accretive for the Softgel business. The only other place where we see mix issues meaningfully impacting the number quarter-to-quarter would be in the clinical supply business. Where we may have lumpy performance on comparative sales, which is a very low margin business versus the rest of the core offering. But we factored that all into our guidance for FY17. So we think we’ve got it cover based on the way that we see our market progressing now.
Matt Walsh: Well, so what tends to move that other expense adjustment line item is a non-cash foreign currency move in danger losses on what is often inter-company debt and so it ends up being pretty unpredictable there even for us.
Matt Walsh: So when we think about that John. We would generally target approximately 70% to 80% of our adjusted net income this year resulting in free cash flow.
Matt Walsh: Well, it’s the underlying reorganization of how we manage the business internally that prompted it. And so during the course of the year, the businesses that now report in the DDS segment are under one business leader within Catalent that Barry Littlejohns is the President of the DDS division. And during the course of the year, he has been afforded more responsibility for those units. So it just make simply that we would then reorganize the reporting structure that way. I actually think this is a very nice improvement. Not just because just the way we manage the business, but because now we have more evenly sized segment, if you recall the prior structure had one relatively large segment and two pretty small ones. Now we’ve got two segments that approximately the same size and the Clinical Services segment being a service oriented short cycle segment on its own that’s now easy to see. So I think it's a good development not just because it is how we manage the business but I think it provides better insight for people that are following the Company or trying to follow the Company.
